13F-HR filed by BVF INC/IL
BVF INC/IL filed this 13F-HR for the quarter ended 2024-12-31, filed 2025-02-14, with 53 holding rows worth $2,950,707,648.
- Accession
- 0000921895-25-000463
- Filer
- CIK 1056807
- Filed
- 2025-02-14
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q4 2024
A holdings report, 53 entries on the cover page, a total value of $2,950,707,648 stated on the cover page (in dollars after the unit check, H1), rows summing to $2,950,707,648 with VALUE read as dollars as filed, 13F file number 028-06800. The quarter's positions are built on this report. The resolved quarter.
Other managers
- included managerBVF PARTNERS L P/IL028-06770
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| MOONLAKE IMMUNOTHERAPEUTICS CLASS A ORD | 61559X104 | Stock | 19,751,284 | $1,069,532,029 | dollars as filed | |
| KYMERA THERAPEUTICS INC | 501575104 | COM | 5,161,801 | $207,659,254 | dollars as filed | |
| REVOLUTION MEDICINES INC COM | 76155X100 | Stock | 4,181,179 | $182,884,769 | dollars as filed | |
| AXSOME THERAPEUTICS INC. COM | 05464T104 | Stock | 1,388,064 | $117,444,095 | dollars as filed | |
| MIRUM PHARMACEUTICALS INC | 604749101 | COM | 2,796,513 | $115,635,813 | dollars as filed | |
| XOMA ROYALTY CORPORATION | 98419J206 | COMMON STOCK | 3,633,743 | $95,494,766 | dollars as filed | |
| PROTAGONIST THERAPEUTICS | 74366E102 | COM | 1,900,015 | $73,340,579 | dollars as filed | |
| GH RESEARCH PLC ORDINARY SHARES | G3855L106 | Stock | 10,400,158 | $72,801,106 | dollars as filed | |
| CULLINAN THERAPEUTICS INC | 230031106 | COM | 5,750,683 | $70,043,319 | dollars as filed | |
| ZYMEWORKS INC | 98985Y108 | COM | 4,308,935 | $63,082,808 | dollars as filed | |
| SEPTERNA INC COM | 81734D104 | Stock | 2,452,024 | $56,151,350 | dollars as filed | |
| TYRA BIOSCIENCES INC | 90240B106 | COMMON STOCK | 3,944,194 | $54,824,297 | dollars as filed | |
| AC IMMUNE SA | H00263105 | SHS | 19,522,436 | $52,710,577 | dollars as filed | |
| XENCOR INC | 98401F105 | COMMON STOCK | 2,288,760 | $52,595,705 | dollars as filed | |
| STRUCTURE THERAPEUTICS INC COMP | 86366E106 | EQUITY | 1,771,417 | $48,040,829 | dollars as filed | |
| CELCUITY INC | 15102K100 | COM | 3,466,000 | $45,369,940 | dollars as filed | |
| LAKEFRONT BIOTHERAPEUTICS NV | 36315X101 | SPON ADR | 1,569,422 | $43,159,105 | dollars as filed | |
| VERVE THERAPEUTICS INC | 92539P101 | COM | 6,904,050 | $38,938,842 | dollars as filed | |
| ANNEXON INC | 03589W102 | COM | 7,000,000 | $35,910,000 | dollars as filed | |
| AGIOS PHARMACEUTICALS INC | 00847X104 | COM | 1,073,755 | $35,283,589 | dollars as filed | |
| 89BIO INC | 282559103 | COM | 4,333,885 | $33,890,981 | dollars as filed | |
| OLEMA PHARMACEUTICALS INC | 68062P106 | COM | 5,715,893 | $33,323,656 | dollars as filed | |
| CIDARA THERAPEUTICS INC | 171757206 | COM NEW | 1,092,796 | $29,374,356 | dollars as filed | |
| ELEDON PHARMACEUTICALS INC | 28617k101 | COM | 6,293,282 | $25,928,322 | dollars as filed | |
| FOGHORN THERAPEUTICS INC | 344174107 | COMMON STOCK | 5,302,000 | $25,025,440 | dollars as filed | |
| THIRD HARMONIC BIO INC | 88427A107 | COM | 2,372,933 | $24,417,481 | dollars as filed | |
| KURA ONCOLOGY INC COM | 50127T109 | Stock | 2,567,469 | $22,362,655 | dollars as filed | |
| ALLAKOS INC | 01671P100 | COM | 16,552,417 | $20,028,425 | dollars as filed | |
| MONTE ROSA THERAPEUTICS INC | 61225M102 | COM | 2,764,471 | $19,185,429 | dollars as filed | |
| ITEOS THERAPEUTICS INC | 46565G104 | COM | 2,325,000 | $17,856,000 | dollars as filed | |
| ESSA PHARMA INC | 29668H708 | COM NEW | 8,748,629 | $15,660,046 | dollars as filed | |
| 4D MOLECULAR THERAPEUTICS INC COM | 35104E100 | Stock | 2,670,642 | $14,875,476 | dollars as filed | |
| RAPT THERAPEUTICS INC | 75382E109 | COM | 9,237,556 | $14,595,338 | dollars as filed | |
| ENGENE HOLDINGS INC | 29286M105 | COM | 2,106,037 | $14,005,146 | dollars as filed | |
| REPARE THERAPEUTICS INC | 760273102 | COM | 10,333,600 | $13,537,016 | dollars as filed | |
| FORTE BIOSCIENCES INC | 34962G208 | COMMON STOCK | 594,282 | $13,496,144 | dollars as filed | |
| VERASTEM INC | 92337C203 | COMMON STOCK | 2,100,468 | $10,859,420 | dollars as filed | |
| Tscan Therapeutics Inc | 89854M101 | COM | 2,989,474 | $9,088,001 | dollars as filed | |
| IMMUNIC INC | 4525EP101 | COM | 8,902,972 | $8,902,972 | dollars as filed | |
| PALVELLA THERAPEUTICS INC | 697947109 | COMMON STOCK | 696,555 | $8,358,660 | dollars as filed | |
| AVALO THERAPEUTICS INC | 05338F306 | COMMON STOCK | 1,036,679 | $7,702,525 | dollars as filed | |
| IKENA ONCOLOGY INC | 45175G108 | COM | 4,006,564 | $6,570,765 | dollars as filed | |
| MOLECULAR PARTNERS AG | 60853G106 | ADS | 1,353,968 | $6,458,427 | dollars as filed | |
| CYTOMX THERAPEUTICS INC | 23284F105 | COMMON STOCK | 5,228,461 | $5,385,315 | dollars as filed | |
| OVID THERAPEUTICS INC | 690469101 | COMMON STOCK | 3,853,818 | $3,598,310 | dollars as filed | |
| SAB BIOTHERAPEUTICS INC | 78397T202 | COMMON STOCK | 917,826 | $3,506,095 | dollars as filed | |
| VIGIL NEUROSCIENCE INC | 92673K108 | COM | 1,813,633 | $3,083,176 | dollars as filed | |
| GLYCOMIMETICS INC | 38000Q102 | COM | 9,544,262 | $2,376,521 | dollars as filed | |
| TENAX THERAPEUTICS INC | 88032L605 | COM NEW | 339,549 | $2,101,808 | dollars as filed | |
| ELEVATION ONCOLOGY INC COM | 28623U101 | Stock | 2,966,836 | $1,669,142 | dollars as filed | |
| INVENTIVA SA | 46124U107 | ADS | 686,040 | $1,474,986 | dollars as filed | |
| ENGENE HOLDINGS INC | 29286M113 | W EXP 10/31/2028 | 945,402 | $803,686 | dollars as filed | |
| NLS PHARMACEUTICS LTD | H57830137 | COM NEW | 143,676 | $303,156 | dollars as filed |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0000921895-25-000463 | this filing | 2025-02-14 | acceptance time not in the bulk data set |